 MONT-SAINT-GUIBERT, Belgium--BUSINESS WIRE--Regulatory News: Celyad Oncology SA Euronext Nasdaq: CYAD Brussels:CYAD Paris:CYAD NASDAQ:CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company will report full year 2021 financial and operating results on the evening of Thursday, March 24th. Following the press release, Celyad management will host a confer 